4Filed Feb 12, 7:00 PM ET

Palisade Bio (PALI) CEO Finley Receives RSUs, Sells 3,896 Shares

$PALI · PALISADE BIO, INC.

Research Summary

AI-generated summary of this SEC filing

Updated

Palisade Bio (PALI) CEO Finley Receives RSUs, Sells 3,896 Shares

What Happened
Finley John David, CEO (also listed as CFO and Director), had 13,333 RSUs converted/settled into common shares on Feb 11, 2026 and subsequently sold 3,896 shares in an open-market transaction on Feb 12, 2026 for $1.75 each, netting $6,818. The Form 4 also shows a derivative conversion entry for 13,333 shares (reported with $0 consideration) related to the RSU settlement.

Key Details

  • Transaction dates: Feb 11, 2026 (RSU settlement / derivative conversion) and Feb 12, 2026 (open-market sale). Form filed Feb 13, 2026 (timely).
  • Shares acquired via conversion/settlement: 13,333 RSUs converted into shares (footnote: issued pursuant to settlement of vested RSUs granted Feb 11, 2025; each RSU = 1 share).
  • Shares sold: 3,896 shares at $1.75 each for $6,818 (footnote: sale was to cover tax withholding obligations related to the RSU vesting).
  • Derivative/technical entry: a conversion/exercise (code M) for 13,333 shares is reported with $0 consideration (reflecting the RSU settlement mechanics).
  • Ownership after transaction: not specified in the excerpt of the filing provided.
  • Additional footnotes: filing notes the Reporting Person is managing member of FCW Investments, LLC (sole investment/voting power over securities held by that entity); RSU award terms indicate vesting in three equal annual installments beginning Feb 11, 2026 (as disclosed).

Context
This was primarily an equity award settlement (RSUs) with a small-sale to cover taxes — a common, routine insider transaction. The conversion of RSUs into shares and the subsequent partial sale do not, by themselves, indicate a buy or sell signal about future company prospects. The filing was submitted within the typical two-business-day window after the transaction dates.